Pfizer Limited
Pfizer Limited Fundamental Analysis
Pfizer Limited (PFIZER.NS) shows strong financial fundamentals with a PE ratio of 27.29, profit margin of 34.39%, and ROE of 21.29%. The company generates $24.8B in annual revenue with moderate year-over-year growth of 4.02%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 68.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze PFIZER.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentPFIZER.NS demonstrates superior asset utilization.
Valuation Score
WeakPFIZER.NS trades at a premium to fair value.
Growth Score
ModeratePFIZER.NS shows steady but slowing expansion.
Financial Health Score
ExcellentPFIZER.NS maintains a strong and stable balance sheet.
Profitability Score
ModeratePFIZER.NS maintains healthy but balanced margins.
Key Financial Metrics
Is PFIZER.NS Expensive or Cheap?
P/E Ratio
PFIZER.NS trades at 27.29 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, PFIZER.NS's PEG of 16.10 indicates potential overvaluation.
Price to Book
The market values Pfizer Limited at 6.05 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 25.94 times EBITDA. This signals the market has high growth expectations.
How Well Does PFIZER.NS Make Money?
Net Profit Margin
For every $100 in sales, Pfizer Limited keeps $34.39 as profit after all expenses.
Operating Margin
Core operations generate 39.04 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $21.29 in profit for every $100 of shareholder equity.
ROA
Pfizer Limited generates $18.53 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Pfizer Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Pfizer Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
PFIZER.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
27.29
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
16.10
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.05
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.38
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.38
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.21
vs 25 benchmark
ROA
Return on assets percentage
0.19
vs 25 benchmark
ROCE
Return on capital employed
0.24
vs 25 benchmark
How PFIZER.NS Stacks Against Its Sector Peers
| Metric | PFIZER.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 27.29 | 29.78 | Neutral |
| ROE | 21.29% | 792.00% | Weak |
| Net Margin | 34.39% | -24634.00% (disorted) | Strong |
| Debt/Equity | 0.04 | 0.25 | Strong (Low Leverage) |
| Current Ratio | 5.38 | 4.60 | Strong Liquidity |
| ROA | 18.53% | -18106.00% (disorted) | Strong |
PFIZER.NS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Pfizer Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
6.03%
Industry Style: Defensive, Growth, Innovation
GrowingEPS CAGR
50.77%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
104.15%
Industry Style: Defensive, Growth, Innovation
High Growth